Effect of pyridoxine alpha-ketoglutarate (PAK) on ammonia and pyruvic and lactic acid blood levels in patients with cirrhosis.
Administration of PAK to patients with hepatic cirrhosis significantly reduced hyperammonaemia and plasma levels of pyruvic and lactic acid. No significant changes in glycaemia were found. PAK treatment increased plasma levels of glutamic acid and decreased plasma levels of glutamine. This double-blind placebo controlled trial showed that PAK administration has a positive effect on some metabolic disturbances in cirrhotic patients.
D000368:Aged; D000596:Amino Acids / Q000097:blood; D000641:Ammonia / Q000097:blood*; D001786:Blood Glucose / Q000378:metabolism; D004311:Double-Blind Method; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007773:Lactates / Q000097:blood*; D019344:Lactic Acid; D008103:Liver Cirrhosis / Q000097:blood* / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D011736:Pyridoxine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011773:Pyruvates / Q000097:blood*; D019289:Pyruvic Acid; D011897:Random Allocation
D000596:Amino Acids; D001786:Blood Glucose; D007773:Lactates; D011773:Pyruvates; C000503:conductase; D019344:Lactic Acid; D000641:Ammonia; D019289:Pyruvic Acid; D011736:Pyridoxine